Atezolizumab for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
Hayworth Cancer Center, High Point, NCNon-Small Cell Lung Cancer+3 MoreAtezolizumab - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is studying a combination of atezolizumab and cobimetinib to treat patients with non-small cell lung cancer.

Eligible Conditions
  • Non-Small Cell Lung Cancer (NSCLC)
  • Non-Small Cell Lung Cancer
  • Stage IV Non-small Cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: Up to 90 days

Day 90
Overall survival (OS)
Day 90
Progression free survival (PFS)
Up to 90 days
Biomarker analysis
Therapeutic procedure
Duration of response
Grade 3 and 4 toxicities
Overall response rate

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Treatment (atezolizumab, cobimetinib)
1 of 1

Experimental Treatment

48 Total Participants · 1 Treatment Group

Primary Treatment: Atezolizumab · No Placebo Group · Phase 2

Treatment (atezolizumab, cobimetinib)Experimental Group · 6 Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Atezolizumab, Cobimetinib · Intervention Types: Procedure, Procedure, Procedure, Procedure, Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4
Biospecimen Collection
Completed Phase 1
Computed Tomography
Completed Phase 2
Magnetic Resonance Imaging
Completed Phase 3
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 90 days

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,153 Previous Clinical Trials
41,162,260 Total Patients Enrolled
Stephen V LiuPrincipal InvestigatorJHU Sidney Kimmel Comprehensive Cancer Center LAO

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You need to have a specific genetic mutation called KRAS, which will be detected by a certified lab test.
You must not have a specific genetic mutation called KRAS in order to participate in cohort 2. Your KRAS mutation status must be known, regardless of cancer type.
You must have a type of disease that can be tested by taking a small tissue sample (core biopsy). You must also be willing to undergo the necessary research biopsies.
You are at least 18 years old.
You have been diagnosed with advanced or recurring non-small cell lung cancer, confirmed by a tissue sample or cell examination.
You have a specific genetic alteration in your EGFR, ALK, or ROS1 genes that can be treated with approved medication, but it hasn't worked or you're unable to tolerate it. If you've tried experimental medication, the study's principal investigator will decide if you're eligible.
You are physically able to perform daily activities without assistance and have a Karnofsky score of 60% or higher.
You have received treatment with anti-PD-1 or anti-PD-L1 medications, either alone or with other drugs, but your disease did not respond to the therapy or it progressed within 6 months. It does not matter if you have received other treatments after this.
You have a specific and measurable lesion that can be seen on a chest x-ray or CT scan, MRI, or by clinical exam. The lesion should be at least 20mm (2cm) for non-nodal lesions and 10mm (1cm) for nodal lesions.
This study is only for adults, as the safety and dosage of the study drugs in children are not yet known. However, there may be future clinical trials specifically for children.

Frequently Asked Questions

Has the FDA granted authorization for Atezolizumab?

"There is existing clinical data that attests to the safety of Atezolizumab, so it was accorded a score of 2." - Anonymous Online Contributor

Unverified Answer

How many facilities are involved in the administration of this experiment?

"The clinical trial is recruiting from the University of Oklahoma Health Sciences Center in Oklahoma City, Wake Forest University at Clemmons in North Carolina and Moffitt Cancer Centre in Tampa Bay. Additionally, there are an additional 9 medical sites participating." - Anonymous Online Contributor

Unverified Answer

How many individuals are receiving treatment as part of this clinical experiment?

"Affirmative. According to information stored on, this medical trial is actively accepting enrolment. Originally posted in July of 2018 and last updated on November of 2022, the research requires 24 individuals across 9 sites." - Anonymous Online Contributor

Unverified Answer

What disease processes can be treated with Atezolizumab?

"Atezolizumab is a commonly prescribed medication to combat certain cases of small cell lung cancer. It may also be used as treatment for metastatic melanoma, unresectable melanoma and other malignant neoplasms." - Anonymous Online Contributor

Unverified Answer

Is recruitment still underway for this experiment?

"Based on the website, this medical trial is still recruiting patients and was initially posted in July 2018 before being updated last November." - Anonymous Online Contributor

Unverified Answer

Has there been previous research conducted on Atezolizumab?

"In 2008, the first trials of atezolizumab began taking place in SCRI Tennessee Oncology Chattanooga. At this time, there have been 101 completed studies and 374 ongoing ones across different locations - particularly Oklahoma City, Oklahoma." - Anonymous Online Contributor

Unverified Answer

Is this a pioneering endeavor in clinical trials?

"Since 2008, Atezolizumab has been the subject of various medical studies. After its initial Phase 1 trial funded by Hoffmann-La Roche in 2008 involving 720 participants, it received approval for a Phase 2 drug trial and is now being researched across 74 countries with 374 active clinical trials occurring in 1651 cities." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.